Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
30 August 2022 | Story André Damons | Photo André Damons
UFS Nuclear Medicine
The team of doctors in the Department of Nuclear Medicine behind the success story are, from the left (standing): Dr Osayande Evbuomwan, nuclear medicine specialist and Senior Lecturer; Dr Gerrit Engelbrecht, Clinical Head of the Department of Nuclear Medicine at the UFS; and Dr Walter Endres, nuclear medicine registrar. In front is Dr Tebatso Tebeila, nuclear medicine registrar.

The University of the Free State (UFS) Department of Nuclear Medicine is proud to announce the successful treatment outcome of a patient with metastatic castrate-resistant prostate cancer (MCRPC) – an advanced stage of prostate cancer – by using Lutetium 177 PSMA (Lu-177 PSMA) therapy. This was initially a case of advanced stage prostate cancer, which had failed first-line chemotherapy, leaving little or no other treatment options.

This is a proud and happy moment for the department and the UFS, which started this treatment just over a year ago. The university and the Free State province are now joining other South African medical universities, such as the University of Pretoria, and other provinces in using this method to treat MCRPC patients. Lutetium 177 PSMA (Lu-177 PSMA) therapy is used on MCRPC patients who are not eligible for chemotherapy or have failed first- or second-line chemotherapy.

Dr Gerrit Engelbrecht, Clinical Head of the Department of Nuclear Medicine at the UFS, says the department is proud to be able to offer this treatment option to some of these patients. “It is a big win for the Free State and our oncology patients to be able to offer these expert services.” The UFS and Universitas Academic Hospital have now been able to join up with other academic institutions and hospitals in other provinces to offer these services. So far, three patients have been offered this therapeutic option, with the third patient currently undergoing his treatment.

Funds and equipment for proper treatment selection are needed

The expertise is no longer an issue for the UFS, as Dr Osayande Evbuomwan, nuclear medicine specialist and consultant, was trained and exposed to this therapy at the University of the Witwatersrand during his training as a nuclear medicine resident. Current registrars in the Department of Nuclear Medicine at the UFS are also being trained in the application of this treatment modality. However, proper patient selection is key in the management of these cases with Lu 177 PSMA. Without a PET/CT camera, it is challenging to appropriately select the patients who are most likely to respond to this therapy. This is an example of how PET/CT is crucial in the management and monitoring of oncology patients.

Both Drs Engelbrecht and Evbuomwan hope that the training of more registrars will increase their department’s capacity to treat more patients. They also hope that funds will be made available to acquire a much-needed PET/CT camera, which will greatly assist them in identifying the correct patients in need of this treatment. 

With the permission of the patient, the images above show the dramatic treatment response following Lu-177 PSMA therapy. The images on the left show widespread bone disease from the prostate cancer, including the skull. The images on the right show the dramatic response after completing four cycles of Lu 177 PSMA, with the normal excretion of the radiotracer seen in the liver, kidneys, and bladder.


Treatment puts the department, UFS, and hospital on the map

According to Dr Evbuomwan, the ability to administer this treatment puts the department, the UFS, and the hospital on the map, alongside other top universities within and outside the country. Says he: “It also creates an avenue for us to gather data for training, research purposes, and publications. We are now able to offer a promising, safe, and highly efficacious therapy for patients with MCRPC in the Free State. Some of these patients will no longer have to travel to other provinces to receive this treatment.”


“We are also well aware that not every patient will respond this way; however, proper patient selection is key in identifying responders – an area that is still being researched. We also do not know how long these patients will have their disease under control after the treatment. Nuclear medicine’s greatest cancer therapy success story is the treatment of well-differentiated thyroid cancer with radioactive iodine.” 

“After treatment, most of these patients remain cancer-free for a very long period of time, if not for life. With continuing research in the field of MCRPC radioligand therapy, we aim to improve the treatment modality, hopefully getting it to the success level of thyroid cancer therapy.”

 

News Archive

Discovery in Scorpius constellation may signify clean energy for Earth
2017-01-23

 Description: Discovery in Scorpius constellation may signify clean energy for Earth Tags: Discovery in Scorpius constellation may signify clean energy for Earth

Earlier this year, a group of international astronomers
announced the discovery of an exotic binary star system,
AR Scorpii. The system is in the Scorpius constellation.
Photos: Supplied

See article on Nature’s website 

In future, stargazers and astronomers will look at the Scorpius constellation near the Milky Way with new eyes. Earlier this year, a group of international astronomers announced the discovery of an exotic binary star system, AR Scorpii. The system is in the Scorpius constellation.

Prof Pieter Meintjes, researcher in the Department of Physics at the University of the Free State (UFS), worked with four colleagues on what he describes as a “wonderful discovery”. This sensational discovery, which could lead to the production of cleaner energy on Earth, will be published in the research journal, Nature, early in 2017.

Model developed to interpret new set of measurements
The exotic binary star which was discovered consists of a red dwarf and a white dwarf revolving around each other every 3,5 hours. The binary system showed very prominent pulsations of 117 and 118 seconds respectively. The pulsations can be explained by a bundle radiation produced by the white dwarf star.

“These new observations have shown that the radiation is strongly polarised, a sign that we are dealing with synchrotron radiation here. Synchrotron radiation is produced by electrons accelerated to extremely high energy levels in the magnetic field of the white dwarf star,” says Prof Meintjes.

He developed a theoretical model to interpret a new set of measurements that was taken by the 1,9 m telescope and the 10 m SALT telescope at the South African Astronomical Observatory (SAA0).

Totally unique phenomenon could contribute to energy production on Earth
“I further indicated that the interaction between the magnetic fields of the white dwarf star and the red dwarf star induces secondary processes that specifically describe the behaviour of the radiation in the radio band and infrared band accurately. AR Sco is the first white-red dwarf binary system of which all the pulsated radiation could be explained by the synchrotron process, which is totally unique,” says Prof Meintjes.

According to Prof Meintjes, the value of the model lies in the fact that the processes which produce the radiation in AR Sco, can also be applied to produce energy on Earth.

 

Plasma reactors are based on roughly the same processes which apply in AR Sco, and with refining, it could be utilised to generate electricity in future. This will be much cleaner than nuclear energy.

 

The model developed by Prof Meintjes explains all the radiation in the system – from radio waves to X-rays – in terms of electrons accelerated to extremely high energy levels by electric fields in the system, which then produce synchrotron radiation over a very wide band of the electromagnetic spectrum.

Prof Meintjes is currently working on a follow-up article examining the evolution of the AR Sco, in other words, the origin of such a unique system and the final state towards which it is evolving. “My vision for the immediate future is therefore to develop a model for the evolution of the source concerned,” he says.

 

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept